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Table S1. Clinical Isolates used in this study 
 
Isolate ID Organism source Date of Isolation 
KP1 Blood Culture 12/04/2016 
KP2 Blood Culture 08/03/2016 
KP3 Tissue 10/01/2016 
KP4 Tissue 07/12/2015 
KP5 Blood Culture 05/10/2015 
KP6 Blood Culture 25/09/2015 
KP7 Blood Culture 01/09/2015 
KP8 Ascitic Fluid 23/02/2015 
KP9 Tissue/Kidney Stone 05/12/2014 
KP10 Blood Culture 27/10/2014 
KP11 Screening Swab 10/10/2014 
KP12 Blood Culture 01/10/2014 
KP13 Groin swab 02/07/2014 
KP14 Wound swab 11/06/2014 
KP15 Blood Culture 20/05/2014 
KP16 Blood Culture 20/04/2014 
KP17 Sputum 19/03/2014 
KP18 Catheter urine 18/02/2014 
KP19 Catheter urine 17/10/2013 
KP20 Sputum 01/08/2013 
KP21 Sputum 30/07/2013 
KP22 Blood Culture 27/07/2013 
KP23 Wound swab 23/07/2013 
KP24 Mid-stream urine 23/07/2013 
KP25 Blood Culture 22/07/2013 
KP26 Mid-stream urine 03/07/2013 
KP27 Central Line Tip 17/04/2013 
KP28 Bronchio-alveolar Lavage (BAL) 11/03/2013 
KP30 Blood Culture 07/08/2012 
KP31 Blood Culture 06/07/2016 
KP32 Tissue 05/07/2016 
KP33 Pus 05/07/2016 
KP34 Tissue 28/06/2016 
KP38 Blood Culture 21/06/2016 
KP40 Blood Culture 09/06/2016 
  
KP46 Tissue 22/04/2016 
KP47 Blood Culture 22/04/2016 
KP48 Peritoneal Fluid 01/04/2016 
KP50 Pus 23/03/2016 
KP59 Blood Culture 25/02/2016 
 
  


















Primer Sequence (5’ to 3’) Reference 
gyrA - F AATATGCGCCATCAGCCC (S1) 
gyrA - R  TGCGAGAGAAATTACACC (S1) 
parC - F ATGAGCGATATGGCAGAGC This work 
parC - R CCACTTCCCGCAGGTTGT This work 
oqxR - F TTCCTGACGCCGGTGTTTTA (S2) 
oqxR - R CTGCGGTGCCAAAAAGAACA (S2) 
ramR - F CTGCAGTGCCCGGTGAACCCTGGCGT (S3) 
ramR - R  CTGCAGATTTGCTGATTCAGCAGCGAC (S3) 












Table S3. Mutations identified in the oqxR  
 




















Effects on OqxR sequence of mutations identified in oqxR in Ecl8 mutants (alleles oqxR1 to 
12) or in the K. pneumoniae clinical isolates (KP9, 12 etc). All these mutations have been 
shown to result in loss of function, and so OqxAB hyper-production. 
  
Table S4: Disc susceptibility testing according to CLSI protocol (26) for K. pneumoniae Ecl8 






Mutation/Transformation CIP LEV NOR OFL 
Ecl8 S S S S Wildtype 
Ecl8 (pEX-K4) S S S S Vector only 
Single acquisition events 
gyrA1 S S S S GyrA:Ser83Phe 
gyrA2 S S S S GyrA Ser83Tyr 
gyrA3 S S S S GyrA Asp87Tyr 
      
oqxR1 S S S S OqxR:Tyr109STOP 
oqxR2 S S S S OqxR:Leu89FS 
oqxR3 S S S S OqxR:Ala37Glu 
oqxR4 S S S S OqxR:Ala133Val 
      
∆ramR S S S S deleted RamR 
ramR S S S S RamR:Thr124Pro 
      
(qnrA1) S S S S QnrA1 
      
(aac(6′)-Ib-cr) S S S S Aac(6′)-Ib-cr 
Double acquisition events 
oqxR1 + gyrA2 NS NS NS NS 
OqxR:Tyr109STOP +  
GyrA:Ser83Tyr 
      
∆ramR + gyrA1  NS NS S NS deleted RamR + GyrA:Ser83Phe 
∆ramR + oqxR5 S S NS S deleted RamR + OqxR:Arg93Cys 
      
(qnrA1 + aac(6′)-Ib-cr) S S S S QnrA1+ Aac(6′)-Ib-cr 
      
gyrA1 (pEX-K4) S S S S GyrA:Ser83Phe Vector only 
gyrA1 (qnrA1) S S S S GyrA:Ser83Phe + QnrA1 
gyrA1 (aac(6′)-Ib-cr) S S S S GyrA:Ser83Phe + Aac(6′)-Ib-cr 
      
  
oqxR1 (pEX-K4) S S S S OqxR:Tyr109STOP Vector only 
oqxR1 (qnrA1) NS NS NS NS OqxR:Tyr109STOP + QnrA1 
oqxR1 (aac(6′)-Ib-cr) S S S S 
OqxR:Tyr109STOP +  
Aac(6′)-Ib-cr 
      
∆ramR (pEX-K4) S S S S deleted RamR Vector only 
∆ramR (qnrA1) NS NS NS NS deleted RamR + QnrA1 
∆ramR (aac(6′)-Ib-cr) S S S S deleted RamR + Aac(6′)-Ib-cr 
Triple acquisition events 
∆ramR + oqxR5 + gyrA1  NS NS NS NS 
deleted RamR + OqxR:Arg93Cys + 
GyrA:Ser83Phe 
      
gyrA1 (qnrA1 +  
aac(6′)-Ib-cr) 
NS S NS S 
GyrA:Ser83Phe + QnrA1 + 
Aac(6′)-Ib-cr 
      
oqxR1 (qnrA1 +  
aac(6′)-Ib-cr) 
NS S NS NS 
OqxR:Tyr109STOP + QnrA1 + 
Aac(6′)-Ib-cr  
      
∆ramR (qnrA1 +  aac(6′)-
Ib-cr) 
NS S S S 
deleted RamR + QnrA1+ 
Aac(6′)-Ib-cr 
      
oqxR1 + gyrA2 (pEX-K4) NS NS NS NS 
OqxR:Tyr109STOP + 
GyrA:Ser83Tyr Vector only 
oqxR1 + gyrA2 (qnrA1) NS NS NS NS 
OqxR:Tyr109STOP + 
GyrA:Ser83Tyr + QnrA1 
oqxR1 + gyrA2  
(aac(6′)-Ib-cr) 
NS NS NS NS 
OqxR:Tyr109STOP + 
GyrA:Ser83Tyr + Aac(6′)-Ib-cr 
      
∆ramR + gyrA1 (pEX-K4) NS NS S NS 
deleted RamR + GyrA:Ser83Phe 
Vector only 
∆ramR + gyrA1 (qnrA1) NS NS NS NS 
deleted RamR + GyrA:Ser83Phe + 
QnrA1 
∆ramR + gyrA1  
(aac(6′)-Ib-cr) 
NS S NS S 
deleted RamR + GyrA:Ser83Phe + 
Aac(6′)-Ib-cr 
∆ramR + oqxR5 (pEX-K4) S S S S 
deleted RamR + OqxR:Arg93Cys  
Vector only 
∆ramR + oqxR5 (qnrA1) NS NS NS NS 
deleted RamR + OqxR:Arg93Cys + 
QnrA1 
∆ramR + oqxR5 (aac(6′)-
Ib-cr) 
S S S S 




Quadruple acquisition events 
oqxR1 + gyrA2  
(qnrA1 + aac(6′)-Ib-cr) 
NS NS NS NS 
OqxR:Tyr109STOP + GyrA:Ser83Tyr 
+ QnrA1 + Aac(6′)-Ib-cr 
      
∆ramR + gyrA1   
(qnrA1 + aac(6′)-Ib-cr) 
NS NS NS NS 
deleted RamR + GyrA:Ser83Phe + 
QnrA1  + Aac(6′)-Ib-cr 
∆ramR + oqxR5 +  
(qnrA1 + aac(6′)-Ib-cr) 
NS NS NS NS 
deleted RamR + OqxR:Arg93Cys + 
QnrA1 + Aac(6′)-Ib-cr 
      
∆ramR + oqxR5 + gyrA1 
(pEXK4) 
NS NS NS NS 
deleted RamR + OqxR:Arg93Cys + 
GyrA:Ser83Phe Vector only 
∆ramR + oqxR5 + gyrA1 
(qnrA1) 
NS NS NS NS 
deleted RamR + OqxR:Arg93Cys + 
GyrA:Ser83Phe + QnrA1 
∆ramR + oqxR5 + gyrA1 
(aac(6′)-Ib-cr) 
NS NS NS NS 
deleted RamR + OqxR:Arg93Cys + 
GyrA:Ser83Phe + Aac(6′)-Ib-cr 
Quintuple acquisition event 
∆ramR + oqxR5 + gyrA1 
(qnrA1 + aac(6′)-Ib-cr) 
NS NS NS NS 
deleted RamR + OqxR:Arg93Cys + 
GyrA:Ser83Phe + QnrA1 +  
Aac(6′)-Ib-cr 
 
a K. pneumoniae Ecl8 is the parental strain in all cases.  
b CIP, ciprofloxacin; LEV, levofloxacin; NOR, norfloxacin; OFL, ofloxacin 
Zone diameter values for definition of susceptible (S) /non-susceptible (NS) designation 
were the means of three repetitions rounded to the nearest integer. Definitions were made 
by reference to susceptibility breakpoints set by the CLSI (29). 
 
  
Table S5: Initial predictive rules and “reduced permeability correction” for ciprofloxacin 
susceptibility in K. pneumoniae 







OqxR RamR Qnr Aac(6')-Ib-cr (MIC [mg.mL-1]) 
1 +     S (0.25) S (1) 
2  +    S (0.25) S (1) 
3   +   S (0.125) S (0.5) 
4    +  S (0.063) S (0.25) 
5     + S (0.016) S (0.063) 
6 + +    NS NS 
7 +  +   NS NS 
8 +   +  S (1) NS (4) 
9 +    + S (0.5) NS (2) 
10  + +   S (0.25)  S (1) 
11  +  +  NS NS 
12  +   + S (0.5) NS (2) 
13   + +  NS NS 
14   +  + S (0.063) S (0.25) 
15    + + S (0.5) NS (2) 
16 + + +   NS NS 
17 + +  +  NS NS 
18 + +   + NS NS 
  
19 +  + +  NS NS 
20 +  +  + NS NS 
21 +   + + NS NS 
22  + + +  NS Ns 
23  + +  + S (1) NS (4) 
24  +  + + NS NS 
25   + + + NS NS 
26 + + + +  NS  NS 
27 + + +  + NS NS 
28 + +  + + NS NS 
29 +  + + + NS NS 
30  + + + + NS NS 
31 + + + + + NS NS 
+; mutation identified or PMQR present, blank; no mutation or PMQR absent, 
NS (Non-susceptible) and shaded blue. S; susceptible and not shaded as defined in 
Table S4 
“RP” (Reduced Permeability) rules to be applied when the OmpF:OmpC ratio is <0.5. 
MICs were determined when isolates were designated susceptible, RP correction is 
4-fold, as described in the text. Susceptibility breakpoints applied for these isolates 
are MIC breakpoints defined by CLSI (29). 
  
Table S6: Final predictive rules for ciprofloxacin susceptibility in K. pneumoniae clinical 
isolates. 











OqxR RamR Qnr Aac(6')-Ib-cr  
1RP +      S (1) 
2RP   +    S (1) 
3RP    +   S (0.5) 
4RP     +  S (0.25) 
5RP      + S (0.063) 
6RP +  +    NS 
7RP +   +   NS 
8RP +    +  NS (4) 
9RP +     + NS (2) 
10RP   + +   S (1) 
11RP   +  +  NS 
12RP   +   + NS (2) 
13RP    + +  NS 
14RP    +  + S (0.25) 
15RP     + + NS (2) 
16RP +  + +   NS 
17RP +  +  +  NS 
  
18RP +  +   + NS 
19RP +   + +  NS 
20RP +   +  + NS 
21RP +    + + NS 
22RP   + + +  Ns 
23RP   + +  + NS (4) 
24RP   +  + + NS 
25RP    + + + NS 
26RP +  + + +  NS 
27RP +  + +  + NS 
28RP +  +  + + NS 
29RP +   + + + NS 
30RP   + + + + NS 
31RP +  + + + + NS 
32RP + +     NS (4) 
33RP + + +    NS 
34RP + +  +   NS 
35RP + +   +  NS 
36RP + +    + NS 
37RP + + + +   NS 
38RP + + +  +  NS 
39RP + + +   + NS 
40RP + +  + +  NS 
  
41RP + +  +  + NS 
42RP + +   + + NS 
43RP + + + + +  NS 
44RP + + + +  + NS 
45RP + + +  + + NS 
46RP + +  + + + NS 
47RP + + + + + + NS 
+; mutation identified or PMQR present, blank; no mutation or PMQR absent, 
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